Sleep and psychiatry by Abad, Vivien C. & Guilleminault, Christian
ental illness exacts a heavy toll on individuals,
families,and society.In 1998,an estimated 44.3 million
people in the USA suffered from a diagnosable mental
disorder.Twenty-nine thousand three hundred and fifty
people died from suicide in 2000, and suicide was the
third leading cause of death in the 15- to 24-year age-
group.
1 Using the Disability Adjusted Life Years mea-
sure,the Global Burden of Disease Study reported that
psychiatric disorders constitute 15.4% of the total dis-
ease burden in established market economies.
2
Psychiatric disorders are frequently associated with dis-
turbances of sleep and circadian rhythms.The relation-
ship between psychiatric disorders and sleep complaints
is bidirectional.In a community survey of 7954 people in
different major US cities from 1981 to 1985, Ford and
Kamerow reported that more subjects met the criteria
for mental illness among those with complaints of insom-
nia (40%) or hypersomnia (46.5%),compared with sub-
jects without any sleep complaints (16.4%).
3 In a study
of 14 915 subjects from the UK, Germany, Italy, and
Portugal, aged 15 to 100 years, Ohayon and Roth
reported that 28% of subjects with insomnia had a cur-
rent diagnosis of mental disorders,and 25.6% had a prior
psychiatric history. In most cases of mood disorders,
insomnia appeared prior to (~40%) or simultaneously
with (~22%) mood disorder symptoms.
4 However,when
anxiety disorders were involved,insomnia appeared at
the same time (~38%) or after (~34%) the onset of the
anxiety disorder.
4 In another study,21% of insomniacs
had symptoms of major depression, while 13% had
symptoms of generalized anxiety.
5 Persistent childhood
sleep problems can herald adult anxiety disorders.In a
prospective longitudinal study of 943 children (52%
male),Gregory et al
6 found that persistent sleep prob-
lems in childhood predicted the development of anxiety
disorders (odds ratio [OR] =1.60,95% confidence inter-
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Psychiatric disorders constitute 15.4% of the disease bur-
den in established market economies. Many psychiatric
disorders are associated with sleep disturbances, and the
relationship is often bidirectional. This paper reviews the
prevalence of various psychiatric disorders, their clinical
presentation, and their association with sleep disorders.
Among the psychiatric disorders reviewed are affective
disorders, psychosis, anxiety disorders (including post-
traumatic stress disorder), substance abuse disorders, eat-
ing disorders, and attention deficit/hyperactivity disorders.
The spectrum of associated sleep disorders includes insom-
nia, hypersomnia, nocturnal panic, sleep paralysis, hypn-
agogic hallucinations, restless legs/periodic limb move-
ments of sleep, obstructive sleep apnea, and parasomnias.
The effects on sleep of various psychotropic medications
utilized to treat the above psychiatric disorders are sum-
marized.   
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(e-mail: cguil@stanford.edu)val [CI] 1.05-2.45,P=0.030),but not depressive disorders
(OR=0.99,95% CI 0.63-1.56,P=0.959),during adult life.
6
Our review will describe various psychiatric disorders,
their associated sleep complaints,and polysomnographic
findings.
Mood (affective) disorders
Mood disorders are mental disorders characterized by
one or more episodes of depression or partial or full
manic or hypomanic episodes.The spectrum of affective
disorders includes major depressive disorder (MDD)
(unipolar depression), bipolar disorder, cyclothymia
(mild bipolar swings),or dysthymia (neurotic or reactive
depression).
A seasonal pattern is common in patients with bipolar
disorders,with onset of depressive episodes during the
fall or winter, and remission during spring.The preva-
lence of winter-type seasonal pattern increases with
higher latitudes.Seasonality is more frequently seen in
younger individuals and in women. Major depressive
episodes are associated with prominent anergy,hyper-
somnia,overeating,weight gain,and craving for carbo-
hydrates.
7
Approximately two-thirds of depressed patients com-
plain of insomnia (sleep-onset insomnia,frequent awak-
enings,and early morning awakenings 2 to 4 hours ear-
lier than desired,with difficulty returning to sleep),while
15% complain of hypersomnia.
8,9 Women who are
depressed are more likely to report insomnia than men.
10
Subjects with persistent insomnia have a higher risk of
developing new major depression (OR=39.8) compared
with those whose insomnia symptoms resolve (OR=1.6).
3
Similar findings were reported in a 3-year longitudinal
epidemiological study of 979 adults (aged 21 to 30 years),
where the relative risk of developing major depression
was four times that in subjects with insomnia,while sub-
jects with hypersomnia had a 2.9 relative risk when com-
pared to subjects without sleep complaints.
11 Moreover,
history of prior insomnia remains a significant predictor
of subsequent major depression, and a recurring com-
plaint of insomnia for 2 weeks or more signals the onset
of major depression.
11 Additionally, sleep disturbance
may be a risk factor for suicide.
Functional neuroimaging studies can differentiate
between primary insomnia and depression, as demon-
strated in a controlled clinical trial of 25 depressed sub-
jects,10 primary insomnia subjects,and 28 healthy con-
trols.
12 Insomnia subjects demonstrated greater waking
metabolism in the frontal pole and ventral prefrontal cor-
tex,showing greater reductions in metabolism from wak-
ing to non–rapid eye movement (NREM) sleep than
depressed patients.
12 During sleep, insomnia subjects
showed increased metabolism in the brain stem,anterior
cingulate, and midbrain arousal structures, while
depressed subjects showed elevated metabolism in a ven-
tral and posterior emotional neural network that per-
sisted into sleep.
12
Major depressive disorder
Sleep disturbances can be an early debilitating symptom
of MDD.Nine million nine hundred adults in the USA
suffer from MDD,and it is the leading cause of disability
in the USA and other established markets worldwide.
1
Depression is more prevalent in women (6.5%) com-
pared with men (3.3%).
1The prevalence of depression is
unaffected by ethnicity,education,income,or marital sta-
tus.
7 First-degree relatives of depressed individuals have
a higher probability of developing depression and also
have a higher risk of alcohol dependence.
7 There is a
higher risk of attention-deficit/hyperactivity disorder
(ADHD) in children of depressed adults.
7
Major depression consists of depressed mood or loss of
interest lasting at least 2 weeks,accompanied by anhe-
donia,significant weight loss or change in appetite,psy-
chomotor agitation or retardation, fatigue or loss of
energy, feelings of worthlessness or excessive or inap-
propriate guilt,decreased ability to concentrate or think,
and suicidal ideation or attempt.
7,13The typical course of
untreated mood disorder is to gradually resolve over 6 to
18 months.
State of the art
292
Selected abbreviations and acronyms
ADHD  attention-deficit/hyperactivity disorder
HI hyperactivity-impulsivity
MDD major depressive disorder
MSLT mean sleep latency test
NREM non–rapid eye movement
PD panic disorder
PTSD posttraumatic stress disorder
REM rapid eye movement
SRE sleep-related eating
SWS slow-wave sleep
TST total sleep time
WASO wakefulness after sleep onsetCircadian temperature rhythm may demonstrate low
amplitude during untreated depression,with return to a
normal rhythm following successful somatic therapy.
Growth hormone secretion may be increased during the
day and decreased at night. Cortisol secretion is
increased,and there is loss of amplitude in the circadian
cortisol pattern.In addition to abnormalities in circadian
pattern,sleep disturbances in patients with major depres-
sion are associated with elevated levels of inflammatory
markers,interleukin-6,and soluble intercellular adhesion
molecules, which are not accounted for by other con-
founding factors,such as age and body weight.
14
Sleep in depressed individuals is disturbed,and complaints
of almost daily insomnia or hypersomnia are common.
Depressed subjects report nocturnal restlessness,feeling
tired,waking up too early,and being unable to return to
sleep.Sleep-onset difficulties are more prominently seen
with younger subjects,whereas problems with sleep con-
tinuity are more characteristic of older subjects.The char-
acteristic insomnia associated with depression is a harbin-
ger of the mood change,often beginning before the clinical
depression has been clearly established.
13
In addition to insomnia and hypersomnia, other sleep
abnormalities have also been reported in association with
depression.In the Wisconsin Sleep Cohort study of 812
participants from 1998 to 2002,depression was associated
with a 2.0-fold increase in hypnagogic hallucinations
(≥1/month), 2.1-fold increase in automatic behavior
(≥1/month),5.1-fold increase in sleep paralysis (≥1/month),
and 1.3-fold increase in cataplexy (≥1/month).
15
Polysomnographic abnormalities can be seen in 40% to
60% of outpatients and 90% of inpatients with a depres-
sive episode.
7 Sleep continuity is impaired with prolon-
gation of sleep latency in younger subjects, increase in
intermittent wakefulness,and early morning awakenings.
Slow-wave sleep (SWS) is reduced (decreased percent-
age of stage 3 to 4 NREM sleep), and delta activity is
decreased, as demonstrated by period-amplitude or
power spectral analysis.Quantitative electroencephalo-
graphic (EEG) studies may show a change in the delta
sleep ratio between the first and second NREM period,
reduced amplitude of slow-wave activity in the first
NREM period, and decreased interhemispheric beta 
and theta coherence and intrahemispheric coherence
between beta and delta rhythms.
16-20 Rapid eye movement
(REM) sleep is enhanced,with increased percentage of
REM sleep and phasic movements during REM sleep.
Temporal characteristics of sleep are altered with short-
ened REM sleep latency, reduced delta activity in the
first NREM period relative to the second (reduced “delta
sleep ratio”), increased phasic eye movement activity,
and increased REM sleep duration during the first REM
period.
7,13,21,22 Analysis of the cyclic alternating pattern
reveals an increase in phases A2 and A3 and a decrease
in phase A1 during NREM sleep highlighting an insta-
bility of NREM sleep in depressed patients.
23
Dysthymic disorder
Like MDD,sleep in other affective disorders,such as dys-
thymic disorder,is also disturbed.Approximately 5.4% of
the US population aged 18 and older suffers dysthymia
during their lifetime.In the USA,10.9 million American
adults are affected.
1Women are affected two to three times
more frequently than men.Dysthymia is characterized by
at least 2 years of frequent depressed mood accompanied
by various symptoms.In a study of 512 dysthymic patients,
Serretti et al reported that the most frequent symptoms in
depressed subjects were low energy or fatigue (96%),poor
concentration or indecisiveness (88%), low self-esteem
(80%),insomnia or hypersomnia (77%),poor appetite or
overeating (69%),and feelings of hopelessness (42%).
24
Children or adolescents with dysthymic disorder are
cranky, irritable, depressed, pessimistic, and have poor
social skills. Individuals with a family history of major
depression respond better to antidepressant medications
than dysthymic individuals without this history.
7
In about 25% to 50% of dysthymic adults, polysomno-
graphic findings are similar to those seen in MDD subjects,
with shortened first NREM period, shortened REM
latency, and increased REM density.
7,13 In a study of 12
hypersomnic dysthymic subjects, Dolenc et al reported
excess stage 1 NREM sleep and reduced stages 3 and 4
NREM sleep on polysomnography;mean sleep latency on
the mean sleep latency test (MSLT) was normal at 13±1
min.
25 As in MDD, an unresolved issue is whether the
sleep-related complaints are due to a circadian rhythm dis-
turbance or to an intrinsic sleep dysfunction.
Bipolar disorder
Bipolar disorder affects 2.3 million Americans.
1 Bipolar I
disorder consists of one or more manic or mixed episodes
usually accompanied by a major depressive episode.
7,13
On the other hand,bipolar II disorder consists of one or
more major depressive episodes accompanied by at least
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7 Like dysthymia,bipolar II dis-
order is more frequent in women,while bipolar I disor-
der does not have a gender difference.Compared with
manic subjects, bipolar depression is associated with
higher sleep efficiency.Polysomnographic findings in the
depressed phase are similar to those of MDD.
During the manic episode of either bipolar I or II disor-
der, a persistent and abnormally elevated, expansive
mood lasting at least 1 week is noted. Accompanying
symptoms include inflated self-esteem or grandiosity,
increased talkativeness,flight of ideas,distractibility,psy-
chomotor agitation,and an excess involvement in plea-
surable activities that have a high potential for painful
consequences.During the manic phase,there is decreased
need for sleep (eg,subject feel rested after only 2 to 4 h
of sleep). Polysomnography in manic subjects demon-
strates markedly decreased total sleep time (TST),and
short REM latency;stages 3 and 4 NREM sleep may be
reduced.
13,22
Cyclothymic disorder
The manic and depressed phases of bipolar disorder are
more severe than the mood fluctuations of cyclothymic
disorder.The essential feature of this disorder is a chronic
(at least 2 years’ duration in adults or at least 1 year’s dura-
tion in children and adolescents) fluctuating mood distur-
bance,with hypomanic symptoms and numerous periods
with depressive symptoms that do not meet criteria for a
major depressive episode.
7,13 During hypomanic episodes,
there is a profound inability to fall asleep.Depressed sub-
jects complain of nocturnal restlessness and tired feelings,
and polysomnographic findings demonstrate abnormali-
ties in sleep continuity and sleep architecture,with reduced
delta sleep and short REM latency.
Anxiety disorders
Similar to depressed subjects,subjects with anxiety dis-
orders also experience sleep difficulties.Over 19 million
American adults aged 18 to 54 years (13.3% of this age
group) suffer from anxiety disorders.
1 Common sleep dis-
turbances associated with anxiety disorders are sleep-
onset or sleep maintenance insomnia.Additionally,some
subjects develop sedative or hypnotic abuse,further com-
plicating their sleep disturbances.Anxiety disorders are
mental disorders characterized by symptoms of anxiety
and avoidance behavior.The spectrum of anxiety disor-
ders encompasses generalized anxiety disorder,panic dis-
order (PD),and posttraumatic stress disorder (PTSD).
Generalized anxiety disorder
Four million American adults suffer from generalized anx-
iety disorder.
1 It is a chronic (≥6 months) condition of
excessive worrying,which is difficult to control.The anxi-
ety is frequently associated with three or more of the fol-
lowing:restlessness or feeling “keyed up,”easy fatigability,
difficulty concentrating or “the mind going blank,” irri-
tability,muscle tension,and difficulty initiating or main-
taining sleep or restless unsatisfying sleep.
7,13
Polysomnography shows nonspecific findings of increased
sleep latency,reduced sleep efficiency,increased amounts
of stages 1 and 2 NREM sleep,reduced SWS,increased
frequency and duration of awakenings, normal or
increased REM sleep latency,and decreased REM sleep
percentage.
26-28 Positive correlations have been reported
between anxiety ratings and number of awakenings,
latency to stage 1 NREM sleep,and percentage of stage 2
NREM sleep.
27
Panic disorder
PD is another anxiety disorder associated with sleep
problems.Two million four hundred thousand American
adults aged 18 to 54 years have PD
1;the average age of
onset is in the late 20s.
13Women are affected two to three
times more frequently than men,and the disorder tends
to run in families.
13Adults with PD frequently have a his-
tory of childhood separation anxiety disorder.PD is char-
acterized by discrete episodes of intense fear or terror of
dying,accompanied by dizziness,choking,palpitations,
trembling,chest pain or discomfort,and sweating.PD can
be associated with secondary depressive symptoms,alco-
holism,sedative or hypnotic abuse,and agoraphobia.
Nocturnal panic (NP) episodes occur in 44% to 71% of
PD patients and are associated with sudden awakening
with the onset of typical panic symptoms.
29,30The subject
is hyperaroused and has difficulty returning to sleep.
30
Comparing patients with NP (n=51) to patients with PD
without a history of NP (n=41),Craske et al reported no
evidence of more severe psychopathology on measures
of PD severity,comorbidity,or interpersonal functioning,
and only weak evidence for more sleep disturbance in
patients with NP.
29
In addition to insomnia, other sleep complaints may
State of the art
294include sleep paralysis and hypnagogic hallucinations.
Recurrent sleep paralysis has been reported by 59% of
African-Americans and 7% of whites with PD,compared
with 23% of African-American and 6% of white com-
munity volunteers.
31Among a psychiatric population of
100 Cambodian refugees,42 subjects had panic attacks
and sleep paralysis; of this subgroup, 91% (38/42)
reported hypnagogic visual hallucinations.
32 Night terrors
and somnambulism can also occur with PD.
33
Patients with PD appear to differ in autonomic regula-
tion when compared with normal subjects,and there are
small differences between patients with daytime panic
attacks and those with sleep-related panic attacks.
34 In a
controlled trial comparing heart rate variability (HRV)
in response to sodium lactate challenge in patients with
PD (n=12 with daytime panic, n=12 with sleep-related
panic) and normal subjects (n=12),a marked subjective
response was noted in the PD patients,but not in control
subjects.Although the 3 groups showed changes in HRV
in response to sodium lactate challenge,HRV decrease
was more pronounced in the group of PD patients com-
pared with control subjects. During NREM sleep, the
value for total power (TP) was significantly higher in the
nocturnal panic patients.The PD patients as a group had
higher values for TP and low-frequency power during
REM sleep than control subjects.The PD patients had
lower sleep efficiency and less stage 4 sleep than control
subjects.
34There were no significant differences between
the two PD groups in sleep architecture.
Polysomnography in PD patients demonstrates margin-
ally increased sleep,reduced sleep efficiency,and abrupt
awakening with sensation of panic out of stage 2 NREM
sleep toward the transition to SWS.
13 Rarely, panic
episodes may occur at sleep onset.Specific treatment of
the sleep disturbance may be needed,since Cervena et al
reported that conventional therapy of PD in 20 subjects
was not sufficient to treat the coexisting insomnia.
35
Posttraumatic stress disorder
Similar to PDs,insomnia is also frequently seen in subjects
with PTSD.In America,5.2 million adults aged 18 to 54
years suffer from PTSD.PTSD results from exposure to a
traumatic episode during which the subject experienced,
witnessed,or was confronted with an event or events which
involved actual or threatened death, serious injury, or
threat to the physical integrity of self or others, and the
subject responded with either intense fear,helplessness,or
horror.The traumatic event is persistently reexperienced
through recurrent and intrusive distressing recollections of
the events,recurrent distressing dreams of the event,act-
ing or feeling as if the traumatic event were recurring,or
intense psychological distress or physiological reactivity on
exposure to external or internal cues that symbolize or
resemble an aspect of the traumatic event.
13 Consequently,
there is numbing of general responsiveness and persistent
avoidance of stimuli associated with the trauma.In addi-
tion, persistent symptoms of hyperarousal (not present
before the traumatic event) occur, including difficulty
falling or staying asleep,irritability or outbursts of anger,
difficulty concentrating,hypervigilance,and exaggerated
startle response.
In a study of 10 PTSD subjects (mean age 34.6 years old,
SD=6.3 years,n=7 women) compared with 7 normal con-
trols using Cohen’s d effect sizes,PTSD subjects showed
longer sleep latency (d=0.57), increased number and
duration of nocturnal awakenings (d=1.06 and d=0.93,
respectively),and reduced TST (d=1.42).
36 Quantitative
EEG analysis demonstrated that PTSD subjects had
greater beta activity (d=0.36) and reduced delta activity
(d=1.45).
36 Preliminary heart period analyses comparing
4 PTSD subjects with 4 control subjects suggested that
parasympathetic tone is lower in PTSD than healthy sub-
jects during NREM (d=3.14) and REM (d=2.20) sleep.
These findings indicate that sleep disruption occurs in
PTSD, as demonstrated by visually scored sleep, EEG
power spectrum,and heart period analysis.
36
Among a group of 21 subjects with acute traumatic injury,
the development of PTSD was associated with more peri-
ods of REM sleep and shorter average duration of REM
sleep before stage shifts to either NREM sleep or wake.
37
Similar findings of increased arousals from REM sleep
were noted in PTSD subjects who participated in a com-
munity-based cohort of young adults followed longitudi-
nally over 10 years.
38 Polysomnographic findings in chronic
PTSD are variable, with normal or reduced sleep effi-
ciency, normal or increased nocturnal awakenings,
increased REM density,and increased phasic muscle acti-
vation during REM sleep.
39-44
Psychoses
Schizophrenia
Sleep disruption is also noted in psychotic disorders,such
as schizophrenia.These disorders are characterized by
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or inappropriate affect that impair interpersonal rela-
tions,work or education,or self-care.There are 2.2 mil-
lion American adults (1.1% of adults age 18 or older)
who are schizophrenic.
1 Onset is usually between late
teens and mid-30s,and both men and women are equally
affected.Acute psychosis is often associated with signif-
icant sleep disruption and severe difficulty initiating
sleep. Extreme anxiety and delusional preoccupation
may result in motor hyperactivity. Partial or complete
inversion of the day-night cycle or reversion to a
polyphasic sleep pattern is observed.Reduced sleep effi-
ciency may occur prior to psychotic decompensation.
Sleep patterns vary, and polysomnographic findings
depend on whether the patient is experiencing the first
episode and is neuroleptic-naive,or is chronically ill.The
sleep disturbances of either never-medicated or previ-
ously treated schizophrenia patients are characterized by
sleep-onset and maintenance insomnia.
45 In 11 first-
episode and neuroleptic-naive patients with schizophre-
nia, Poulin et al reported prolonged sleep latency,
decreased stage 4 duration,reduced REM sleep latency,
normal sleep spindles,and normal REM densities,indi-
cating difficulty initiating but not maintaining sleep.
46
However,others have reported decreased TST,signifi-
cant disruption in sleep continuity, shortened REM
latency,normal or increased REM density with variable
REM time,and normal or decreased SWS.
13,45,47-50
After REM sleep deprivation,acute schizophrenics have
no REM sleep rebound,while chronic schizophrenics with
no active symptoms have more rebound than normal.
51-53
With neuroleptic treatment and clinical improvement over
3.5 weeks,Maixner et al demonstrated improvements in
sleep continuity (sleep latency decreased, time spent
asleep increased,and sleep efficiency improved) and an
increase in REM latency and SWS during follow-up
polysomnography.
54 However, despite improvement in
these measures during neuroleptic treatment,these para-
meters remained abnormal when compared to normative
data.
54 In a longitudinal study of schizophrenic subjects
comparing baseline sleep data to results at 4 weeks and 
1 year after starting treatment,Keshavan et al reported
significant improvement in sleep continuity measures and
modest increase in REM latency,with no other changes in
sleep architecture at 4 weeks,while at 1 year,REM latency,
REM duration, and average automated REM counts
increased without significant changes in SWS parameters.
55
These findings suggest that SWS parameters are relatively
stable during follow-up,while REM parameters may vary
in relation to the phase of illness and treatment.In addi-
tion to the sleep disturbances noted above,a study of psy-
chiatric hospital inpatients referred for sleep evaluation
reported higher rates of obstructive sleep apnea in schiz-
ophrenia patients.
56 However,the schizophrenia patients
had history of chronic neuroleptic usage and were heavier
than patients with other disorders.
56
Current theory on schizophrenia proposes an imbalance
between dopaminergic and acetylcholinergic influences
on key central nervous system (CNS) structures, such
that dopaminergic activity is increased during the psy-
chotic phase,and a compensatory increase in muscarinic
acetylcholinergic activity results in increased negative
symptoms.
22,57 Tandon et al reported decreased REM
sleep latency and increased REM density in association
with the negative symptoms of schizophrenia and attrib-
uted these to increased CNS muscarinic activity.
50
Treatment of schizophrenia and other psychoses may lead
to use of new atypical antipsychotic medications.Some of
these drugs have important metabolic effects associated
with induction of insulin resistance and leptin resistance.
These abnormalities are seen mostly during the nocturnal
period and are associated with development of significant
weight gain and obesity.Due to these metabolic and body
mass index (BMI) changes,patients may develop obstruc-
tive sleep apnea and associated sleep disruption.With use
of some of these atypical antipsychotic drugs, the BMI
increase is rapid and treatment with nasal chronic positive
airway pressure (CPAP) may be needed.
Substance-induced sleep disorder
As seen with mood disorders,anxiety disorders,and psy-
chosis,sleep is also impaired in subjects with substance
abuse. Sleep problems during childhood (ages 3 to 5
years) appear to be markers for increased risk of abuse
of alcohol,marijuana,and illicit drugs later in life.
58
Alcohol abuse
Acute alcohol ingestion during the first half of the night
increases sleepiness,prolongs TST,reduces wakefulness
after sleep onset (WASO) lasting for 3 to 4 h,increases
SWS,and reduces REM sleep.During the second half of
the night,alcohol leads to increased sleep fragmentation,
increased WASO, restless sleep, reduced SWS, and
increased REM sleep with vivid and anxiety-laden
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habitual use,the short-lived sedative effect of alcohol is
followed by disruption of sleep continuity.
13 Insomnia is
a common complaint,reported by 36% to 72% of alco-
holics; this symptom may persist for weeks to months
after initiation of abstinence.
59Among patients entering
treatment for alcoholism,insomnia has been significantly
associated with subsequent alcoholic relapse.
59 During
alcohol withdrawal, sleep is grossly disturbed with
extremely disrupted sleep continuity,increased WASO,
REM sleep rebound with an increase in the amount and
intensity of REM sleep,vivid dreaming,and,occasionally,
delirium.After acute withdrawal,subjects with chronic
alcohol use may complain of light fragmented sleep last-
ing for months to years,and the EEG shows persistent
deficit in SWS and persistent sleep continuity distur-
bances.
7
Stimulant-dependent sleep disorder
Stimulant-dependent sleep disorder consists of reduction
in sleepiness or suppression of sleep by central stimu-
lants, with alterations in wakefulness following absti-
nence. Central stimulants include phenylethylamines
(amphetamine, ephedrine), cocaine, thyroid hormone,
and various xanthine derivatives (caffeine,theophylline).
Individuals who abuse or self-administer central stimu-
lants have sustained periods of total sleep suppression,
often followed by periods of deep hypersomnolence.
Drug administration is frequently associated with
increased behavior activity progressing to states of hypo-
mania,garrulousness,paranoid ideation,and repetitive
behavior.
13As tolerance to the alerting effect of the stim-
ulant occurs,higher doses are utilized,and,later,periods
of high-dosage drug administration are interrupted only
by periods of somnolence that result from exhaustion,
following a prolonged period of sleep suppression.Acute
toxicity may result in cardiac arrhythmias,intracerebral
hemorrhage, convulsions, and respiratory arrest.
Withdrawal from chronic amphetamine use develops
within a few hours and lasts for several days after cessa-
tion. Symptoms include dysphoria, fatigue, vivid and
unpleasant dreams,insomnia or hypersomnia,increased
appetite, and psychomotor retardation. “Crashing,”
resulting from acute withdrawal after periods of repeti-
tive high-dose use of amphetamines or cocaine,is asso-
ciated with intense lassitude and depression, and even
suicidal ideation.
Polysomnographic recordings during acute intoxication
with stimulants demonstrate increased sleep latency,
decreased TST,increased spontaneous awakenings with
increased body movements during sleep, prolonged
REM latency, and reduced total REM time. Stimulant
withdrawal is associated with reduced sleep latency and
increased TST with hypersomnia and prolongation of
nocturnal sleep duration.
7,13 REM and SWS may rebound
to greater than baseline values.MSLT during the with-
drawal phase shows increased sleepiness with mean sleep
latency <10 min.
Sedative-, hypnotic-, and anxiolytic-dependent 
sleep disorder
The inverse of stimulant abuse is abuse of sedative-hyp-
notic agents.Hypnotic-dependent sleep disorder presents
with excessive sleepiness or insomnia associated with tol-
erance to or withdrawal from sedative-hypnotic medica-
tions.Sleep complaints and objective measures of sleep
are affected by the differences in duration of action and
half-life of the various sedative-hypnotic agents.
7 During
acute intoxication, sedative-hypnotic drugs produce
hypersomnolence and decrease wakefulness.
7 Chronic
usage, however, may lead to tolerance, with return of
underlying insomnia,and,if the dose is increased,day-
time hypersomnia,sluggishness,ataxia,slurred speech,
and visual-motor problems with late-afternoon restless-
ness and nervousness,can occur.
13 Polysomnography in
subjects using hypnotic agents demonstrates disrupted
sleep architecture with an increase in stage 2 NREM
sleep, reduction in stages 1, 3, and 4 NREM sleep, and
reduction in REM sleep.
22 Both NREM and REM sleep
are fragmented, with frequent sleep-stage transitions.
Increased 14 to 18 Hz spindles are seen together with
increased alpha and beta activity.Sedative-hypnotics can
also aggravate underlying breathing disorders.
Abrupt discontinuation of chronic sedative-hypnotic use
can result in withdrawal insomnia,decreased sleep dura-
tion, increased anxiety, tremulousness, and ataxia.
7
Although sleep architecture rapidly improves,subjective
complaints of sleep quality and quantity will be deemed
greater than before hypnotic therapy commenced.
13
Abrupt discontinuation of chronic use of barbiturates
and the older nonbarbiturate,nonbenzodiazepine drugs
is associated with a higher incidence of withdrawal
seizures compared to benzodiazepines.Shorter-duration
sedative-hypnotic drugs can result in withdrawal insom-
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cause daytime hypersomnia during active use.However,
any sedative-hypnotic agent can produce either with-
drawal insomnia or daytime sedation.Polysomnography
during withdrawal demonstrates reduced sleep duration,
increased sleep disruption,and REM sleep rebound.
Eating disorders
As with substance abuse disorders,patients with eating dis-
orders also go through phases of indulgence and with-
drawal,and have associated sleep-related problems.Eating
disorders consist of severe disturbances in eating behavior,
and the spectrum encompasses anorexia nervosa,bulimia,
and sleep-related eating disorder.
60-66
Anorexia nervosa
About 90% of anorexia nervosa occurs in females,and the
prevalence of this condition among women in late adoles-
cence and early adulthood is approximately 0.5% to 1.0%.
13
Peak onset occurs bimodally at ages 14 and 18 years.
Essential features include refusal by the individual to main-
tain a minimally normal body weight,intense fear of gain-
ing weight,and a significant disturbance in body perception
(shape or size).Subsets include restricting type (weight loss
is induced by fasting,dieting,or vigorous and excessive exer-
cise) and binge-eating/purging type.In anorexia nervosa
individuals,insomnia together with other depressive symp-
toms,such as depressed mood,irritability,and decreased
libido, can also be present.
7 Long-term mortality is over
10% due to starvation,suicide,or electrolyte imbalance.
7
Bulimia nervosa
This eating disorder occurs in 1% to 3% of adolescent and
young female adults,and is characterized by binge-eating
and inappropriate compensatory methods to prevent
weight gain.These behaviors must occur on the average at
least twice a week for 3 months.Subsets include the purg-
ing type (use of self-induced vomiting or misuse of laxa-
tives,diuretics,or enemas during the current episode) or
the nonpurging type in which abnormal behaviors,such as
fasting or excessive exercise,are utilized.Bulimic individ-
uals are usually within the normal weight range,although
some are slightly underweight or overweight.Anxiety or
depressive symptoms frequently occur.Sleepwalking has
also been reported in bulimic individuals.
Nocturnal eating (drinking) syndrome
Like sleepwalking,nocturnal eating/drinking syndrome
represents a parasomnia.This sleep disorder is charac-
terized by recurrent awakenings with inability to return
to sleep without eating or drinking.This problem occurs
primarily during infancy and early childhood, with a
prevalence of 5% in children between ages 6 months to
3 years. Nighttime waking can become conditioned to
hunger and eating. After consuming the expected
amount of food or drink, return to sleep is rapid.The
prevalence in adults is unknown,but appears more com-
mon in women. Manni et al reported 5.8% prevalence
among 120 adult subjects (51 males,69 females,mean age
42.6 years) referred for insomnia complaints.
60
Schenck et al described 19 adults with sleep-related eat-
ing (SRE),with mean age of onset of 24.7±9.1 years,and
reported that psychiatric disorders affected 47.4% (9/19)
of these patients; 31.6% (6/19) were diagnosed with
affective disorders,while 21.0% (4/19) had anxiety dis-
orders.
61 Winkelman reported that 35% (8/23) of their
patients with SRE had a lifetime eating disorder diagno-
sis.
63 Symptoms in SRE include eating almost on a nightly
basis (1-6 times per night),preferential consumption of
high-caloric foods, binging or “out of control” eating,
food preparation/consumption ranging from elaborate to
sloppy,associated injuries from cooking/eating,including
sustaining burns,dreamlike mentation with descriptions
of being “half-awake,”“half-asleep,”and “asleep”asso-
ciated with “consistent”or “occasional”amnesia for the
event.
61-63 Patients complained of weight gain,concerns
about choking while eating,starting fires from cooking,
and sleep disruption.
61 Polysomnographic recordings doc-
umented complex behaviors arising abruptly from
NREM sleep (stages 2 and 3 to 4) and occasionally also
from REM sleep. Excessive numbers of arousals from
NREM sleep were documented.Complex behaviors dur-
ing polysomnographic recording ranged from moaning
to somniloquy (logical or nonsensical),yelling,disorga-
nized limb movements and thrashing,gesturing and fin-
ger pointing,throwing punches,sitting up abruptly,look-
ing around in a confused manner with open eyes,
grabbing at either hallucinated or actual bedside objects,
picking up and handling the electrode jack box with per-
plexity, and kicking and attempting to leave the bed.
61
Accompanying EEG changes with SRE ranged from
persistence of stage 2 or 3 to 4 to rapid complete
arousal.
61,62Two forms of disordered arousals,each with
State of the art
298multiple precipitants, can result in SRE: confusional-
amnestic arousals associated with somnambulism,tria-
zolam abuse,narcolepsy,sleep apnea,and psychotropic
medications, or alert arousals associated with periodic
movements of sleep or autoimmune hepatitis.
61
Attention-deficit/hyperactivity disorder
Like the eating disorders,ADHD can impair quality of
life and can be associated with sleep problems.ADHD
consists of a persistent pattern (≥6 months) of inattention
and/or hyperactivity-impulsivity (HI) that is maladaptive
and inconsistent with an individual’s developmental
level.
7,13 The prevalence is estimated at 3% to 5% of
school-age children in the USA.
7 The disorder is more
frequent in males,with male to female ratio of 4:1 to 9:1.
7
Three subtypes occur: combined, predominantly inat-
tentive (attention-deficient),and predominantly hyper-
active-impulsive (HI).
Various sleep disorders have been reported as associated
with ADHD.In a prospective controlled study of adults
with restless legs syndrome (n=62) or insomnia (n=32)
and adult controls (n=77),ADHD symptoms were more
common in restless legs syndrome patients (26%) than
insomnia patients (6%) or controls (5%) (P<0.01).
67
Restless legs and periodic leg movements of sleep were
also correlated in children with ADHD.In a cross-sec-
tional survey of 866 children aged 2.0 to 13.9 years (mean
6.8±3.2 years), Chervin et al reported that positive HI
scores (>60) were found in 13% of all subjects,18% of
children with restless legs,and 11% of children without
restless legs (chi-square P<0.05).
68 ORs between HI>60
and each of the following were: a 1-SD increase in the
overall PLMS score,OR=1.6;restless legs,OR=1.9;and
growing pains,OR=1.9 (all age- and sex-adjusted).Poor
sleep quality and increased sleepiness associated with
ADHD children can be due to either periodic leg move-
ments of sleep or sleep-disordered breathing.
68,69
Habitual snoring is more common in ADHD children
(33%) compared with 11% in a psychiatry clinic and 9%
in a general pediatric clinic.
70 Another cross-sectional
study of 45 ADHD children reported that only the HI
subtype of ADHD correlated with chronic snoring.
71 In
a cross-sectional survey of 866 children aged 2.0 to 13.9
years (mean 6.8±3.2 years),the OR between HI>60 and
a 1-SD increase in the overall sleep disordered breathing
score was 1.7.
68,69 In two other studies,sleep-disordered
breathing occurred in 50% (17/34) to 76% (67/88) of
ADHD children,and periodic limb movements of sleep
were reported in 10% (9/88) to 15% (5/34).
72,73
Polysomnographic recordings of ADHD children com-
pared with normal controls demonstrate an increase in
the percentage of phase 3 of sleep.
74 Epileptic paroxysms
have also been reported in 16.7% of ADHD children.
74
In addition to behavioral measures, medications have
been utilized in ADHD;like other psychotropic medica-
tions,these can also affect sleep.
Sleep effects of medications 
and substances of abuse
Sleep architecture can be affected by acute or chronic
ingestion of medications or substances of abuse,as well as
by abrupt withdrawal of these agents. Antidepressant
drugs consist of tricyclic antidepressants (TCAs),selective
serotonin reuptake inhibitors (SSRIs),monoamine oxi-
dase inhibitors (MAOIs), and noradrenaline reuptake
inhibitors (NARIs).Acute intake of TCAs,except trim-
ipramine, decreases WASO, increases stage 2 NREM
sleep,increases delta sleep,and reduces REM sleep with
varying degrees of residual daytime sedation.During with-
drawal, WASO is increased and REM sleep rebound
occurs.Trimipramine ingestion increases SWS,but has no
effect on REM sleep. MAOIs, such as moclobemide,
phenelzine,and trancylpromine,increase sleep continuity,
increase REM sleep latency, and reduce REM sleep
amount,but do not affect SWS.However,moclobemide
can result in insomnia.
75,76Acute ingestion of SSRIs may
cause insomnia or hypersomnia.WASO may be normal or
increased, but SWS is not affected. REM latency is
increased and REM sleep is reduced.SSRI agents,such as
fluoxetine, sertraline, and paroxetine, may induce sleep
bruxism,which may improve with buspirone.
75,77-79Acute
ingestion of trazodone decreases WASO,increases or has
no effect on SWS,and decreases or has no effect on REM
sleep.Buproprion reduces REM latency,increases REM
sleep,and normalizes a propensity for sleep-onset REM
periods on multiple sleep latency testing.
75 Mirtazapine
increases SWS,but does not affect stage 2 NREM sleep,
nor does it affect REM latency or REM percentage of
total sleep.NARIs increase the duration of stage 2 NREM
sleep,lengthen REM latency,and shorten REM sleep.
Mood stabilizers are used for bipolar disorders and include
lithium and anticonvulsant drugs. Lithium ingestion
acutely decreases REM sleep and increases delta sleep.
Anticonvulsant drugs utilized in bipolar disorders include
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gabapentin, lamotrigine, tiagabine, and zonisamide.
Valproic acid disrupts sleep by increasing stage 1 sleep.
80
Carbamazepine increases sleep efficiency,shortens sleep
latency,decreases REM percentage of TST,and decreases
REM density.
75,80 Gabapentin increases REM sleep per-
centage,increases mean duration of REM periods,reduces
number of awakenings,reduces stage 1 sleep percentage,
and increases SWS.
80-82 Lamotrigine increases REM sleep,
reduces the number of entries into REM sleep,decreases
the number of phase shifts,and decreases the percentage
of SWS.
81Tiagabine significantly increases sleep efficiency,
decreases wakefulness,and increases SWS and low-fre-
quency activity during NREM sleep.
83 Zonisamide is asso-
ciated with daytime somnolence and fatigue.
Like the antidepressants,antipsychotic medications have
different effects on sleep.Traditional neuroleptic agents
(dopamine [D2/D3] antagonists, such as thorazine,
haloperidol) increase sleep onset, sleep efficiency, and
stage 3 NREM sleep;reduce REM sleep;increase peri-
odic limb movements of sleep;and may induce restless
legs syndrome–like akathisia.The newer non-D2 neu-
roleptics,such as clozapine,olanzapine,and risperidone,
increase sedation,reduce SWS,and increase restless legs
syndrome and periodic leg movements.Use of quetiap-
ine fumarate can result in insomnia.Withdrawal of nar-
coleptics results in reduction in sleep continuity and
REM sleep.As mentioned previously,some of the atyp-
ical antipsychotic drugs have important metabolic effects,
with development of obesity and subsequent obstructive
sleep apnea.Atypical antipsychotics vary in their poten-
tial to cause metabolic abnormalities: olanzapine and
clozapine carry the highest risks;risperidone and queti-
apine have lower risks;and ziprasidone and aripiprazole
have minimal metabolic risks.
84,85 Psychotic patients who
relapse have greater reductions in TST,sleep efficiency,
total NREM sleep,and stage 2 NREM sleep compared
to nonrelapsers.
75
Antianxiety drugs and hypnotic drugs,such as barbitu-
rates and benzodiazepines,also affect sleep.Acute inges-
tion of barbiturates leads to increased TST, decreased
WASO, increased stage 2 NREM sleep with increased
spindles, variable effects on SWS, and reduced REM
sleep. Tolerance to barbiturates rapidly develops, and
withdrawal leads to insomnia and reduced TST.Acute
ingestion of benzodiazepines decreases sleep latency
(agents vary in onset),increases TST,increases stage 2
NREM sleep and spindles,decreases WASO and REM
sleep, and usually suppresses stages 3 and 4 NREM
sleep.
22Withdrawal from benzodiazepines reduces TST.
Rebound insomnia lasting for one to two nights occurs
following withdrawal from short-acting benzodiazepines.
Benzodiazepine receptor agents, such as zolpidem or
zaleplon,reduce sleep latency and increase TST,but do
not affect either SWS or REM sleep.Withdrawal from
these agents leads to increased WASO.
Substances of abuse also impact sleep.Acute and chronic
alcohol ingestion and withdrawal from alcohol affect
sleep, as has been described above under substance-
induced sleep disorder.Acute ingestion of opioids,such
as heroin or methadone,profoundly disrupts sleep con-
tinuity and staging with increased brief arousals,reduces
TST,decreases stages 3 and 4 NREM sleep,and reduces
REM sleep.
86-88Withdrawal from methadone can produce
nocturnal insomnia lasting for 3 to 5 weeks. After
methadone withdrawal, REM sleep and delta sleep
increase.
88
Amphetamines and methylphenidate are utilized to treat
ADHD,but also have high abuse liability.Acute inges-
tion of amphetamines increases sleep latency, reduces
sleep efficiency, reduces REM latency, and suppresses
REM sleep. Withdrawal from amphetamines leads to
increased TST and increased REM sleep, which can
remain elevated for three to five nights.Methampheta-
mines increase average daily sleep latency on the MSLT
in a dose-dependent manner for both normal subjects
and narcoleptics.
75 Methlyphenidate reduces TST,
increases REM latency, and reduces REM sleep dura-
tion. Nicotine produces a dose-dependent increase 
in wakefulness and reduction in REM sleep.
Discontinuation of chronic nicotine use leads to
increased number of arousals, awakenings, and sleep
stage changes during the week of cessation.
Conclusions
Sleep problems and psychiatric disorders are codepen-
dent conditions that exacerbate each other and lead to
impaired quality of life and increased disability.
Recognition of the symptoms of these various psychiatric
problems and their associated sleep issues has important
therapeutic implications. ❏
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Sueño y psiquiatría
Los trastornos psiquiátricos constituyen el 15,4% de
los costos de las enfermedades en las economías de
mercado. Muchos trastornos psiquiátricos están aso-
ciados con alteraciones del sueño y la relación a
menudo es bidireccional. Este artículo revisa la pre-
valencia de varios trastornos psiquiátricos, su pre-
sentación clínica y su asociación con los trastornos
del sueño. Entre los trastornos psiquiátricos revisa-
dos están los trastornos afectivos, las psicosis, los
trastornos de ansiedad (incluyendo el trastorno por
estrés postraumático), trastornos por abuso de sus-
tancias, trastornos del comer y trastornos por défi-
cit de atención con hiperactividad. El espectro de
los trastornos del sueño asociados incluye insomnio,
hipersomnia, terror nocturno, parálisis del sueño,
alucinaciones hipnagógicas, síndrome de las pier-
nas inquietas y de los movimientos periódicos del
sueño, apneas obstructivas del sueño y parasom-
nias. También se resumen los efectos sobre el sueño
de diversos psicofármacos utilizados para tratar los
trastornos psiquiátricos mencionados anterior-
mente. 
Sommeil et psychiatrie
Les troubles psychiatriques constituent 15,4 % du
poids médical des économies de marché patentes.
De nombreux troubles psychiatriques sont associés
à des perturbations du sommeil, et le lien est sou-
vent bidirectionnel. Cet article passe en revue la
prévalence de troubles psychiatriques variés, leur
présentation clinique, et leur association aux
troubles du sommeil. Les troubles psychiatriques
examinés comprennent les troubles affectifs, les
psychoses, les troubles anxieux (y compris les
troubles du stress posttraumatique), les troubles liés
à l’abus d’une substance, les troubles des conduites
alimentaires et les troubles du déficit de l’atten-
tion/hyperactivité. Le spectre des troubles du som-
meil associés comprennent l’insomnie, l’hypersom-
nie, la terreur nocturne, la paralysie du sommeil, les
hallucinations hypnagogiques, le syndrome des
jambes sans repos/mouvements périodiques du
sommeil, les apnées obstructives du sommeil et les
parasomnies. Nous résumons ici les effets sur le
sommeil de divers traitements psychotropes utilisés
pour traiter les troubles psychiatriques ci-dessus.
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